Purpose: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are primarily preferred in patients with type 2 diabetes. The purpose of this paper was to elucidate the effects of SGLT-2 inhibitor use on patients' voiding habits, sleep, and quality of life.
Methods: Our study involved patients with type 2 diabetes who had an SGLT2 inhibitor added to their current treatment. The frequency of day-night urination, lower urinary tract symptoms, sleep and quality of life were assessed both prior to initiation of the treatment and during subsequent 1st and 3rd months.
Results: The study included 38 women and 34 men. At the third month after SGLT-2 inhibitor had been added, there was a significant decrease in HbA1c, triglyceride and microalbumin levels (p<0.05). There was no increase in voiding frequency (day/night) and there was no difference in the evaluation of lower urinary tract symptoms, but voiding volumes increased in uroflowmetry. When the short form-36 (SF-36) scale was examined, there was a significant improvement in physical function, one of the sub-parameters (p = 0.01). The factor affecting this most, was the improvement in HbA1c.
Conclusion: This paper suggests that SGLT-2 inhibitors don’t increase voiding frequency and don’t cause an increase in lower urinary tract symptoms.
Sodium-glucose cotrasporter-2 inhibitor lower urinary tract symptoms nocturia quality of life type 2 diabetes.
Birincil Dil | İngilizce |
---|---|
Konular | Endokrinoloji |
Bölüm | Research Article |
Yazarlar | |
Yayımlanma Tarihi | 30 Eylül 2024 |
Gönderilme Tarihi | 13 Haziran 2024 |
Kabul Tarihi | 17 Eylül 2024 |
Yayımlandığı Sayı | Yıl 2024 Cilt: 8 Sayı: 3 |